Axel Kloppe

Axel Kloppe

Auto-generated profile, based on publicly available information

Axel Kloppe

Marienhospital Gelsenkirchen GmbH

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2016 in International Journal of Cardiology
Verified
Journal Article
Closed access
AKAxel Kloppe
Axel Kloppe
TLThomas Lawo
Thomas Lawo
DMDejan Mijic
Dejan Mijic
FSFabian Schiedat
Fabian Schiedat
AMAndreas Muegge
Andreas Muegge
BLBernd Lemke
Bernd Lemke

26 February 2016 in Cardiology Journal
Verified
Journal Article
Open access
AKAxel Kloppe
Axel Kloppe
DMDejan Mijic
Dejan Mijic
FSFabian Schiedat
Fabian Schiedat
HBHarilaos Bogossian
Harilaos Bogossian
AMAndreas Mügge
Andreas Mügge
BLBernd Lemke
Bernd Lemke
Cardiac contractility modulation (CCM) signals are non-excitatory electrical signals delivered during the absolute refractory period intended to improve contraction and cardiac function. Clinical trials have shown that CCM treatment significantly improves exercise tolerance and quality of life in symptomatic heart failure patients. Studies with CCM therapy typically include CCM delivery for 3, 5 or 7 h per day, although other configurations are also commonly used. Each has been associated with improved outcomes in heart failure, but it is not clear whether different application durations are associated with the various degrees of benefit. The purpose of the current pilot evaluation study was to evaluate the quality of life, exercise tolerance, and cardiac function, over a 6-month period when CCM was delivered for 5 h/day vs. 12 h/day. Increasing the daily CCM therapy duration is safe and as good as the standard CCM periods of application per day. This single center pilot evaluation study involved 19 medically refractory symptomatic patients with heart failure and reduced left ventricular function who underwent implantation of an Optimizer™ system (Impulse Dynamics, Orangeburg, NY, USA). Patients were randomized into one of two treatment groups; 5 h/day CCM treatment or 12 h/day CCM treatment. Subjects and evaluating physicians were blinded to the study group. Subjects returned to the hospital after 12 and 24 weeks. Efficacy evaluations included changes from baseline to 24 weeks in Minnesota Living With Heart Failure Questionnaire score (MLWHFQ), maximal oxygen consumption in the cardio-pulmonary stress test (peak VO2), New York Heart Association classification (NYHA), 6-min walk distance (6MWD), and ejection fraction (EF). At the end of 24 weeks, clinical improvement was observed in the entire cohort in all efficacy measures (mean change from baseline of -17.1 in MLWHFQ, -0.86 in NYHA, and improvement trend of 1.48 mL O2/kg/min in peak VO2, 31.3 m in 6MWD, and 2.25% in EF). There were no significant differences, either clinically or statistically, between the groups receiving CCM for 5 h/day vs. 12 h/day. Three subjects were voluntarily withdrawn before completing the study. One subject died from pneumonia after 125 days, and 6 serious adverse events were reported, none of which was classified as related to either the device or the procedure. Together with previously reported experience with CCM, delivery of CCM therapy is equally safe and appears similarly effective over the range of shorter (5 h) to longer (12 h) daily periods of application. Given the small sample size, further studies are warranted.

1 September 2014
Verified
Journal Article
Closed access
MGMichael Gotzmann
Michael Gotzmann
ACAnna Czauderna
Anna Czauderna
AAAssem Aweimer
Assem Aweimer
THTobias Hehnen
Tobias Hehnen
LBLeif Bösche
Leif Bösche
AEAydan Ewers
Aydan Ewers

11 September 2004 in Medical Engineering & Physics
Verified
Journal Article
Closed access
AKA. Kloppe
A. Kloppe
KHK. Hoeland
K. Hoeland
SMS. Müller
S. Müller
MHM. Hexamer
M. Hexamer
GNG. Nowack
G. Nowack
JWJ. Werner
J. Werner
In order to obtain a better physiological performance and a closer restoration of the regular rhythm of failing hearts, a new fiber optical sensor system for the measurement of cardiac contraction has been developed. It consists of an opto-electrical unit and a sensing fiber which has to be positioned in the heart. The objective of this new fiber optic sensor system is to use the inotropic information to adjust a stimulation algorithm in single or multichamber pacing or to detect arrhythmia in insufficient heart function. In this study, the mechanical and optical characteristics of different fibers are investigated. The relationship between the attenuation (with an achieved numerical maximum of 0.3 dB), the bending diameter and the angle of bending is determined in a range of 20-160 mm. The most suitable fiber for the application in cardiological problems is determined (WT8 fiber), for which the sensitivity is analyzed. Additionally, power spectra are calculated from WT8 fiber signals obtained from pig hearts, working under physiological conditions. The maximal frequency response was 23 Hz. It is concluded that the fiber optical measurement of cardiac contraction is not only feasible and reproducible, but the WT8 fiber also shows optimal behavior in the range of parameters occurring in the heart chambers. Nevertheless, in order to restrict the measured signal reliably to bending processes within the chambers only, it is concluded that a special combined fiber has to be constructed with a high sensitivity only at its terminal section within the heart.

1 January 2011 in Journal of Arrhythmia
Verified
Journal Article
Closed access
AKAxel Kloppe
Axel Kloppe
DMDejan Mijic
Dejan Mijic
MZMarkus Zarse
Markus Zarse
BLBernd Lemke
Bernd Lemke

1 June 2005 in EP Europace
Verified
Journal Article
Open access
PDF file
AKA. Kloppe
A. Kloppe
MNM. Neise
M. Neise
TFT. Fortmann
T. Fortmann
DFD. Fllgraf
D. Fllgraf
DBD. Boppert
D. Boppert
BLB. Lemke
B. Lemke
A. Kloppe, M. Neise, T. Fortmann, D. Fllgraf, D. Boppert, B. Lemke; 614 Electrode implantation technique for biventricular pacemaker and ICD. Effective and saf